Literature DB >> 8970997

Role of Vif in human immunodeficiency virus type 1 reverse transcription.

J Goncalves1, Y Korin, J Zack, D Gabuzda.   

Abstract

The Vif protein of human immunodeficiency virus type 1 (HIV-1) is important for virion infectivity. Previous studies have shown that vif mutant HIV-1 virions are defective in their ability to synthesize proviral DNA in vivo. Here, we examine the role of Vif in viral DNA synthesis in the endogenous reverse transcriptase (RT) reaction, an in vitro assay in which virions synthesize viral DNA by using endogenous viral RNA as a template. vif mutant virions showed a significant reduction in endogenous RT activity despite similar levels of exogenous RT activity. Analysis of the viral DNA products on agarose gels demonstrated that this reflects reduced synthesis of short minus- and plus-strand DNA products in addition to those of full genomic length. Quantitative PCR analysis of endogenous reverse transcription provided further evidence for reduced formation of both initial and completed reverse transcripts. Vif had no effect on genomic RNA dimerization or the stability of the RNA dimer linkage. These results suggest that Vif is important for an early event after virus entry but preceding or during the early stages of viral DNA synthesis. This may be due to an intrinsic effect on reverse transcription or a preceding postentry event(s), such as virion uncoating or disassembly of the virion core. Drugs targeted to Vif function may provide a new therapeutic approach to inhibiting HIV-1 reverse transcription.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8970997      PMCID: PMC190965     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  42 in total

1.  A procedure for Northern blot analysis of native RNA.

Authors:  E W Khandjian; C Méric
Journal:  Anal Biochem       Date:  1986-11-15       Impact factor: 3.365

2.  Complete nucleotide sequence of the AIDS virus, HTLV-III.

Authors:  L Ratner; W Haseltine; R Patarca; K J Livak; B Starcich; S F Josephs; E R Doran; J A Rafalski; E A Whitehorn; K Baumeister
Journal:  Nature       Date:  1985 Jan 24-30       Impact factor: 49.962

3.  Replicative and cytopathic potential of HTLV-III/LAV with sor gene deletions.

Authors:  J Sodroski; W C Goh; C Rosen; A Tartar; D Portetelle; A Burny; W Haseltine
Journal:  Science       Date:  1986-03-28       Impact factor: 47.728

4.  The HIV 'A' (sor) gene product is essential for virus infectivity.

Authors:  K Strebel; D Daugherty; K Clouse; D Cohen; T Folks; M A Martin
Journal:  Nature       Date:  1987 Aug 20-26       Impact factor: 49.962

5.  Moloney murine sarcoma virions synthesize full-genome-length double-stranded DNA in vitro.

Authors:  E W Benz; D Dina
Journal:  Proc Natl Acad Sci U S A       Date:  1979-07       Impact factor: 11.205

6.  Characterization of the reverse transcriptase from a new retrovirus (HTLV) produced by a human cutaneous T-cell lymphoma cell line.

Authors:  H M Rho; B Poiesz; F W Ruscetti; R C Gallo
Journal:  Virology       Date:  1981-07-15       Impact factor: 3.616

7.  Viral DNA synthesized in vitro by avian retrovirus particles permeabilized with melittin. I. Kinetics of synthesis and size of minus- and plus-strand transcripts.

Authors:  L R Boone; A M Skalka
Journal:  J Virol       Date:  1981-01       Impact factor: 5.103

8.  In vitro synthesis of infectious DNA of murine leukaemia virus.

Authors:  E Rothenberg; D Smotkin; D Baltimore; R A Weinberg
Journal:  Nature       Date:  1977-09-08       Impact factor: 49.962

9.  The sor gene of HIV-1 is required for efficient virus transmission in vitro.

Authors:  A G Fisher; B Ensoli; L Ivanoff; M Chamberlain; S Petteway; L Ratner; R C Gallo; F Wong-Staal
Journal:  Science       Date:  1987-08-21       Impact factor: 47.728

10.  Secretion of a nerve growth factor by mouse neuroblastoma cells in culture.

Authors:  R A Murphy; N J Pantazis; B G Arnason; M Young
Journal:  Proc Natl Acad Sci U S A       Date:  1975-05       Impact factor: 11.205

View more
  61 in total

1.  Reversion of a human immunodeficiency virus type 1 matrix mutation affecting Gag membrane binding, endogenous reverse transcriptase activity, and virus infectivity.

Authors:  R E Kiernan; A Ono; E O Freed
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

2.  Human immunodeficiency virus type 1 N-terminal capsid mutants that exhibit aberrant core morphology and are blocked in initiation of reverse transcription in infected cells.

Authors:  S Tang; T Murakami; B E Agresta; S Campbell; E O Freed; J G Levin
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

Review 3.  HIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factors.

Authors:  Silke Wissing; Nicole L K Galloway; Warner C Greene
Journal:  Mol Aspects Med       Date:  2010-06-09

4.  Vif is largely absent from human immunodeficiency virus type 1 mature virions and associates mainly with viral particles containing unprocessed gag.

Authors:  P Sova; D J Volsky; L Wang; W Chao
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

5.  The HIV-1 Nef protein enhances the affinity of reverse transcriptase for RNA in vitro.

Authors:  Cécile Fournier; Jean-Claude Cortay; Caroline Carbonnelle; Chantal Ehresmann; Roland Marquet; Pierre Boulanger
Journal:  Virus Genes       Date:  2002-12       Impact factor: 2.332

6.  A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins.

Authors:  Heather L Wiegand; Brian P Doehle; Hal P Bogerd; Bryan R Cullen
Journal:  EMBO J       Date:  2004-05-20       Impact factor: 11.598

7.  Vif is an auxiliary factor of the HIV-1 reverse transcriptase and facilitates abasic site bypass.

Authors:  Reynel Cancio; Silvio Spadari; Giovanni Maga
Journal:  Biochem J       Date:  2004-11-01       Impact factor: 3.857

Review 8.  Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding.

Authors:  Nicolas Sluis-Cremer; N Alpay Temiz; Ivet Bahar
Journal:  Curr HIV Res       Date:  2004-10       Impact factor: 1.581

9.  Anti-HIV-1 efficacy of extracts from medicinal plants.

Authors:  Su-A Lee; Seong-Karp Hong; Chang-Il Suh; Mi-Hwa Oh; Jeong-Ho Park; Byoung-Wook Choi; Seung-Won Park; Soon-Young Paik
Journal:  J Microbiol       Date:  2010-05-01       Impact factor: 3.422

10.  The M184V mutation in reverse transcriptase can delay reversion of attenuated variants of simian immunodeficiency virus.

Authors:  James B Whitney; Maureen Oliveira; Mervi Detorio; Yongjun Guan; Mark A Wainberg
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.